Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models

Vaccine

Volumn 25, Issue 46, 2007, Pages 7955-7961

  Zhu, Kuichun ^a   Qin, Hong ^a   Cha, Soung Chul ^a   Neelapu, Sattva S ^a   Overwijk, Willem ^a   Lizee, Gregory A ^a   Abbruzzese, James L ^a   Hwu, Patrick ^a   Radvanyi, Laszlo ^a   Kwak, Larry W ^a   Chang, David Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

DNA vaccine; Pancreatic carcinoma; Survivin

Indexed keywords

CANCER VACCINE; DNA VACCINE; SURVIVIN DNA VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; SURVIVAL TIME; VACCINATION;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHOCYTES; LYMPHOMA; MICE; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; VACCINES, DNA;

EID: 35448989825     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.050     Document Type: Article

References (40)

1. Reed J.C., and Wilson D.B. Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9 (2003) 6523-6533
2. Reed J.C., and Wilson D.B. Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9 17 (2003) 6310-6315
3. cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97 24 (2000) 13103-13107
4. Reed J.C., and Reed S.I. Survivin' cell-separation anxiety. Nat Cell Biol 1 8 (1999) E199-E200
5. Sarela A.I., Verbeke C.S., Ramsdale J., Davies C.L., Markham A.F., and Guillou P.J. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86 6 (2002) 886-892
6. Satoh K., Kaneko K., Hirota M., Masamune A., Satoh A., and Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92 2 (2001) 271-278
7. Mesri M., Wall N.R., Li J., Kim R.W., and Altieri D.C. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108 7 (2001) 981-990
8. Blanc-Brude O.P., Mesri M., Wall N.R., Plescia J., Dohi T., and Altieri D.C. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9 7 (2003) 2683-2692
9. Qiao J.G., Zhang Y.Q., Yin Y.C., and Tan Z. Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2. World J Gastroenterol 10 18 (2004) 2759-2761
10. Kami K., Doi R., Koizumi M., Toyoda E., Mori T., Ito D., et al. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 136 2 (2004) 443-448
11. Kami K., Doi R., Koizumi M., Toyoda E., Mori T., Ito D., et al. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 138 2 (2005) 299-305
12. Asanuma K., Kobayashi D., Furuya D., Tsuji N., Yagihashi A., and Watanabe N. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res 93 9 (2002) 1057-1062
13. Andersen M.H., Pedersen L.O., Becker J.C., and Straten P.T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 61 3 (2001) 869-872
14. Andersen M.H., Pedersen L.O., Capeller B., Brocker E.B., Becker J.C., and thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61 16 (2001) 5964-5968
15. Casati C., Dalerba P., Rivoltini L., Gallino G., Deho P., Rini F., et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 63 15 (2003) 4507-4515
16. Schmitz M., Diestelkoetter P., Weigle B., Schmachtenberg F., Stevanovic S., Ockert D., Rammensee H.G., and Rieber E.P. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 60 17 (2000) 4845-4849
17. Idenoue S., Hirohashi Y., Torigoe T., Sato Y., Tamura Y., Hariu H., et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 11 4 (2005) 1474-1482
18. Hirohashi Y., Torigoe T., Maeda A., Nabeta Y., Kamiguchi K., Sato T., et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8 6 (2002) 1731-1739
19. Zeis M., Siegel S., Wagner A., Schmitz M., Marget M., Kuhl-Burmeister R., et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170 11 (2003) 5391-5397
20. Ciesielski M.J., Apfel L., Barone T.A., Castro C.A., Weiss T.C., and Fenstermaker R.A. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 55 12 (2006) 1491-1503
21. Zhou H., Luo Y., Lo J.F., Kaplan C.D., Mizutani M., Mizutani N., et al. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci USA 102 31 (2005) 10846-10851
22. Xiang R., Mizutani N., Luo Y., Chiodoni C., Zhou H., Mizutani M., et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65 2 (2005) 553-561
23. Pisarev V., Yu B., Salup R., Sherman S., Altieri D.C., and Gabrilovich D.I. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9 17 (2003) 6523-6533
24. Siegel S., Wagner A., Schmitz N., and Zeis M. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 122 6 (2003) 911-914
25. Otto K., Andersen M.H., Eggert A., Keikavoussi P., Pedersen L.O., Rath J.C., et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 23 7 (2005) 884-889
26. Tsuruma T., Hata F., Torigoe T., Furuhata T., Idenoue S., Kurotaki T., et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Trans Med 2 1 (2004) 19
27. Tsuruma T., Torigoe T., Hata F., Furuhata T., Sato N., and Hirata K. Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy. Gan To Kagaku Ryoho 31 11 (2004) 1634-1636
28. Wobser M., Keikavoussi P., Kunzmann V., Weininger M., Andersen M.H., and Becker J.C. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 55 10 (2006) 1294-1298
29. Steitz J., Bruck J., Steinbrink K., Enk A., Knop J., and Tuting T. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 86 1 (2000) 89-94
30. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9 4 (2003) 1284-1290
31. Gold J.S., Ferrone C.R., Guevara-Patino J.A., Hawkins W.G., Dyall R., Engelhorn M.E., et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 170 10 (2003) 5188-5194
32. Palomba M.L., Roberts W.K., Dao T., Manukian G., Guevara-Patino J.A., Wolchok J.D., et al. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 11 1 (2005) 370-379
33. Lu Y., Wei Y.Q., Tian L., Zhao X., Yang L., Hu B., et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 170 6 (2003) 3162-3170
34. Wang B., Wei D., Crum V.E., Richardson E.L., Xiong H.H., Luo Y., et al. A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. Oncogene 22 12 (2003) 1771-1782
35. Biragyn A., Tani K., Grimm M.C., Weeks S., and Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 17 3 (1999) 253-258
36. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 1 (2005) 10-30
37. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., Andre T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 15 (2005) 3509-3516
38. Reni M, Cordio S, Passardi A, Panucci MG, Passoni P, Oliani C, et al. Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S (July 15 Supplement)):Abstract 4010.
39. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2005:Abstract 1.
40. Guevara-Patino J.A., Engelhorn M.E., Turk M.J., Liu C., Duan F., Rizzuto G., et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 116 5 (2006) 1382-1390